Drug intelligence / Profile preview

Rhino 25 Platinum

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral
01

Overview

Rhino 25 Platinum is an **unapproved sexual enhancement product** marketed as a dietary supplement rather than a legitimate pharmaceutical developed through a regulated drug-development program. Public safety findings indicate that it contains **undeclared sildenafil**, a small-molecule **phosphodiesterase type-5 inhibitor** that increases cyclic guanosine monophosphate signaling and promotes smooth-muscle relaxation in the corpus cavernosum to facilitate erection. The product has been the subject of FDA warnings because the hidden active ingredient creates risks typical of sildenafil exposure, including potentially dangerous hypotension, especially with nitrates, as well as headache, chest pain, and priapism. It is not an approved prescription drug, has no legitimate disclosed developer, and is sold illegally through channels such as convenience stores, gas stations, and online sellers.

Brand names
Rhino 25 PlatinumRhino25 PlatinumRhino-25 PlatinumPlatinum Rhino 25000
Other names
Rhino
02

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on Rhino 25 Platinum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhino 25 Platinum.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call